Heart Failure
Conditions
Keywords
Acute Heart Failure, Chronic Heart Failure, Guideline adherence, Clinical registry
Brief summary
To evaluate if Italian Cardiologists are treating Heart Failure (HF) patients according to International guidelines and if a structured educational program can improved their adherence.
Detailed description
Multicentre, cross-sectional, prospective, non-interventional, observational study designed to evaluate the level of adherence to current ESC guidelines recommendations in both acute and chronic HF patients enrolled in each participating center and to verify if a specific HF educational intervention composed by an educational web based program of data collection and face to face meetings is able to improve adherence to guidelines recommendations evaluated during a second enrollment period.
Interventions
None listed
Sponsors
Heart Care Foundation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All consecutive patients with chronic HF and those admitted for acute (de novo) or worsening chronic HF. * Chronic HF: any NYHA class (I-IV). * Acute HF Only patients in NYHA class III or IV, or with pulmonary edema or cardiogenic shock for whom an IV therapy specific for HF (diuretic, vasodilators, vasopressors) is administered. * Any gender. * Any etiology of HF. * Any level of EF. * Written informed consent.
Exclusion criteria
* \- Age \<18 years. * Inclusion in registries or trials that can influence, by protocol, the clinical management of patients. * Patients already enrolled in the BLITZ HF (by another participating centre or in the first enrollment period).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence to current guideline | Enrollment | To assess number of patients managed and treated following the 2016 ESC Heart Failure Gudelines (acute HF, chronic HFrEF, chronic HFmrEF, chronic HFpEF). |
| Patients managed and treated following International Guideline | 24 months | Patients treatment in phase 1 versus phase 3 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Indication to heart failure device implantation | Enrollement | The rate of patients with chronic HFrEF with an indication to ICD and/or CRT planned in clinical practice |
| Prescription rate of disease modifying drugs | Enrollment | The rate of patients with HFrEF receiving all the drugs recommended by current guidelines: ACE-Is/ARBs, betablockers and MRAs, in the absence of specific contraindications/intolerance. |
| Mortality | 12 months Follow-up | Death from all-causes, for cardiovascular causes, for HF |
| Use of ARNI | Enrollment | The rate of implementation of a new drug approach (ARNI) for patients with HF and EF ≤35% |
| Creatinine and EF evaluation | Enrollment | The rate of CHF patients with an available measure of EF and of creatinine. |
| Oral anticoagulation prescription in patients with AF | Enrollment | Rate of patients treated with oral anticoagulants in case of AF |
| Morbidity | 12 months Follow-up | Hospital admissions from all-causes, for cardiovascular causes, for HF |
Countries
Italy
Outcome results
None listed